Works matching DE "THERAPEUTIC use of monoclonal antibodies"

Results: 5000

Will Nirsevimab Reduce the Burden on Public Health Care?—Reply.

Published in:

JAMA Pediatrics, 2025, v. 179, n. 8, p. 926, doi. 10.1001/jamapediatrics.2025.1552

By:

Moline, Heidi L.;
McMorrow, Meredith L.;
Dawood, Fatimah S.

Publication type:

Article

Will Nirsevimab Reduce the Burden on Public Health Care?

Published in:

2025

By:

Ding, Fangrui

Publication type:

Letter

Omalizumab Efficacy in Chronic Rhinosinusitis Patients with Recurrent Nasal Polyps: An open-label, single-center, randomized, controlled study.

Published in:

Annals of Otology, Rhinology & Laryngology, 2025, v. 134, n. 9, p. 692, doi. 10.1177/00034894251344426

By:

Noeiaghdam, Rafat;
Esmaeilzadeh, Hossein;
Faramarzi, Mohammad;
Moshfeghinia, Reza;
Fallahi, Mohammad Sadegh;
Alyasin, Soheila;
Nabavizadeh, Hesamedin;
Mortazavi, Negar

Publication type:

Article

FDA Grants Accelerated Approval to Zongertinib for Nonsquamous NSCLC With HER2 TKD–Activating Variants.

Published in:: ONS Voice, 2025, p. N.PAG
Publication type:: Article

Effectiveness of Second-Line Pembrolizumab Monotherapy for the Treatment of Nonsmall Cell Lung Cancer: A Retrospective-Single Institution Study of 52 Vietnamese Patients.

Published in:

Clinical Medicine Insights: Oncology, 2025, p. 1, doi. 10.1177/11795549251359142

By:

Tai Nguyen, Van;
Kien Do, Hung;
Van Le, Quang;
Tu Do, Anh;
Chu Nguyen, Van;
Phuong Nguyen, Thi Bich;
Hoa Nguyen, Thi Nhu

Publication type:

Article

First-Line Durvalumab plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice.

Published in:

Oncology, 2025, v. 103, n. 8, p. 742, doi. 10.1159/000542517

By:

Fujii, Yasutoshi;
Kawaoka, Tomokazu;
Shirane, Yuki;
Miura, Ryoichi;
Nakahara, Hikaru;
Yamaoka, Kenji;
Uchikawa, Shinsuke;
Fujino, Hatsue;
Ono, Atsushi;
Murakami, Eisuke;
Miki, Daiki;
Hayes, Nelson Clair;
Tsuge, Masataka;
Nakamura, Yuko;
Awai, Kazuo;
Oka, Shiro

Publication type:

Article

Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution.

Published in:

Oncology, 2025, v. 103, n. 8, p. 677, doi. 10.1159/000541891

By:

Rimini, Margherita;
Foti, Silvia;
Camera, Silvia;
Rossari, Federico;
Vitiello, Francesco;
Lo Prinzi, Federica;
Aldrighetti, Luca;
De Cobelli, Francesco;
Pedica, Federica;
Arcidiacono, Paolo Giorgio;
Persano, Mara;
Cascinu, Stefano;
Casadei-Gardini, Andrea

Publication type:

Article

The Association between Body Mass Index and Mortality in Breast Cancer Patients Receiving Pembrolizumab.

Published in:

Oncology, 2025, v. 103, n. 8, p. 709, doi. 10.1159/000542542

By:

Chiang, Cho-Han;
Xu, Xiaocao;
Shahid, Ahmed;
Song, Junmin;
Chi, Kuan-Yu;
Chang, Yu-Cheng;
Chang, Yu;
Chiang, Cho-Hung;
Lin, Shuwen

Publication type:

Article

Bacterial Protein Offers New Hope in the Fight Against Alzheimer's.

Published in:: Indian Practitioner, 2025, v. 78, n. 7, p. 10
Publication type:: Article

Obinutuzumab as a Promising Treatment for Membranous Nephropathy.

Published in:

Indian Journal of Nephrology, 2025, v. 35, n. 3, p. 1, doi. 10.25259/IJN_391_2024

By:

Meena, Priti;
Ramachandran, Raja

Publication type:

Article

Multi-center phase II study of nab-paclitaxel plus camrelizumab versus nab-paclitaxel alone as second-line treatment for advanced gastric cancer.

Published in:

Oncologist, 2025, v. 30, n. 7, p. 1, doi. 10.1093/oncolo/oyaf189

By:

Sun, Li;
Gong, Zhimin;
Wang, Lei;
Kuang, Li;
Huang, Qiao;
Pei, Bo;
Yuan, Xianglin;
Qiu, Hong

Publication type:

Article

New tool in the toolbox: patient selection for zolbetuximab in advanced treatment-naïve gastric/gastroesophageal junction adenocarcinoma.

Published in:

Oncologist, 2025, v. 30, n. 7, p. 1, doi. 10.1093/oncolo/oyaf185

By:

Grewal, Udhayvir S;
Brown, Timothy J

Publication type:

Article

Real-world outcomes of first-line treatment with HLX02 versus reference trastuzumab plus pertuzumab in HER2-positive metastatic breast cancer.

Published in:

Oncologist, 2025, v. 30, n. 7, p. 1, doi. 10.1093/oncolo/oyaf183

By:

Yan, Ying;
Zhang, Ruyan;
Li, Yanling;
Di, Lijun;
Gui, Xinyu;
Jiang, Hanfang;
Liang, Xu;
Shao, Bin;
Song, Guohong;
Li, Huiping

Publication type:

Article

Long-term safety analysis of pooled data for tislelizumab as monotherapy or in combination with chemotherapy in patients with advanced cancers.

Published in:

Oncologist, 2025, v. 30, n. 7, p. 1, doi. 10.1093/oncolo/oyaf177

By:

Zhou, Caicun;
Huang, Rose;
Yuan, Yuan;
Schnell, Patrick;
Wu, John;
Kadva, Alysha;
Mehmeti, Jola;
Ajani, Jaffer

Publication type:

Article

First-line treatment with HDACis plus tislelizumab combined with chemotherapy in advanced NSCLC: a single-arm phase II study.

Published in:

Oncologist, 2025, v. 30, n. 7, p. 1, doi. 10.1093/oncolo/oyaf155

By:

Wang, Lijie;
Gao, Ming;
Wang, Ting;
Cui, Pengfei;
Chen, Guangying;
Han, Xiao;
Ma, Zhiqiang;
Yang, Wenyu;
Jing, Fangfang;
Ma, Junxun;
Zhang, Fan;
Tao, Haitao;
Hu, Yi

Publication type:

Article

Resistance of recurrent epidermal growth factor receptor-altered glioblastoma to anti-epidermal growth factor receptor targeted therapy with osimertinib.

Published in:

Oncologist, 2025, v. 30, n. 7, p. 1, doi. 10.1093/oncolo/oyaf146

By:

Villanacci, Federico;
Prost, Diego;
Pieri, Francesco;
Boetto, Julien;
Zucchi, Vanna;
Giusti, Andrea;
Jacob, Julian;
Nichelli, Lucia;
Cupini, Samanta;
Allegrini, Giacomo;
Porta, Mauro Della;
Santonocito, Orazio Santo;
Touat, Mehdi;
Stefano, Anna Luisa Di

Publication type:

Article

Moving the needle on immune checkpoint inhibitors with novel targets: are we being TIMid or LAGging behind?

Published in:

Oncologist, 2025, v. 30, n. 7, p. 1, doi. 10.1093/oncolo/oyaf145

By:

Park, Changsu Lawrence;
Bedard, Philippe L

Publication type:

Article

First-in-human phase I open-label study of the anti–TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors.

Published in:

Oncologist, 2025, v. 30, n. 7, p. 1, doi. 10.1093/oncolo/oyaf144

By:

Gutierrez, Martin E;
Tang, Shou-Ching;
Powderly, John D;
Balmanoukian, Ani S;
Hoyle, Paul E;
Dong, Zhiwan;
Cheng, Lulu;
Gong, Xiaohua;
Janik, John E;
Bourayou, Nawel;
Hamid, Omid

Publication type:

Article

First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors.

Published in:

Oncologist, 2025, v. 30, n. 7, p. 1, doi. 10.1093/oncolo/oyaf136

By:

Powderly, John D;
Gutierrez, Martin E;
Balmanoukian, Ani S;
Hoyle, Paul E;
Dong, Zhiwan;
Cheng, Lulu;
Chen, Xuejun;
Janik, John E;
Bourayou, Nawel;
Hamid, Omid

Publication type:

Article

Safety and quality of life with maintenance olaparib plus bevacizumab in older patients with ovarian cancer: subgroup analysis of PAOLA‑1/ENGOT-ov25.

Published in:

Oncologist, 2025, v. 30, n. 7, p. 1, doi. 10.1093/oncolo/oyae322

By:

Montégut, Coline;
Falandry, Claire;
Cinieri, Saverio;
Cropet, Claire;
Montane, Laure;
Rousseau, Frédérique;
Joly, Florence;
Moubarak, Malak;
Mosconi, Anna M;
Guerra-Alía, Eva M;
Schauer, Christian;
Fujiwara, Hiroyuki;
Vergote, Ignace;
Parma, Gabriella;
Lindahl, Gabriel;
Anota, Amélie;
Canzler, Ulrich;
Marmé, Frederik;
Pujade-Lauraine, Eric;
Ray-Coquard, Isabelle

Publication type:

Article

Correction to: Efficacy and Safety of Camrelizumab, Apatinib, and Capecitabine Combination Therapy in Advanced Biliary Tract Cancer: A Single-arm Prospective Study.

Published in:: 2025
Publication type:: Correction Notice

Evaluation of a risk-sharing agreement for atezolizumab treatment in patients with non-small cell lung cancer: a strategy to improve access in low-income countries.

Published in:

Oncologist, 2025, v. 30, n. 7, p. 1, doi. 10.1093/oncolo/oyae272

By:

Arrieta, Oscar;
Ramos-Ramírez, Maritza;
Garcés-Flores, Homero;
Cabrera-Miranda, Luis A;
Gómez-García, Ana Pamela;
Soto-Molina, Herman;
Cardona, Andrés F;
Valencia-Velarde, Ángel;
Gálvez-Niño, Marco;
Guzmán-Vázquez, Silvia

Publication type:

Article

Recaticimab: First Approval.

Published in:

Drugs, 2025, v. 85, n. 8, p. 1067, doi. 10.1007/s40265-025-02199-5

By:

Lamb, Yvette N.

Publication type:

Article

Sipavibart: First Approval.

Published in:

Drugs, 2025, v. 85, n. 8, p. 1049, doi. 10.1007/s40265-025-02186-w

By:

Keam, Susan J.

Publication type:

Article

만성 비부비동염의 치료: 약물치료 및 새로운 치료법을 중심으로.

Published in:

Journal of the Korean Medical Association / Taehan Uisa Hyophoe Chi, 2025, v. 68, n. 7, p. 427, doi. 10.5124/jkma.25.0079

By:

Park, Sang Chul

Publication type:

Article

난치성 비부비동염의 치료.

Published in:

Journal of the Korean Medical Association / Taehan Uisa Hyophoe Chi, 2025, v. 68, n. 7, p. 436, doi. 10.5124/jkma.25.0077

By:

Cho, Jae Hoon

Publication type:

Article

Pretreatment with an anti-CGRP monoclonal antibody attenuates mild TBI-induced tactile hypersensitivity in mice.

Published in:

Journal of Headache & Pain, 2025, v. 26, n. 1, p. 1, doi. 10.1186/s10194-025-02108-x

By:

Wattiez, Anne-Sophie;
Kuburas, Adisa;
Castonguay, William C.;
Fejgin, Kim;
Klewe, Ib V.;
Russo, Andrew F.

Publication type:

Article

The need of preexposure prophylaxis against COVID-19 in immunocompromised patients– an assessment from Germany.

Published in:

Infection, 2025, v. 53, n. 4, p. 1541, doi. 10.1007/s15010-025-02540-w

By:

Gerstenberg, Jacob;
Lübbert, Christoph;
Widera, Marek;
Schleenvoigt, Benjamin T.

Publication type:

Article

Echovirus serotype 11 induced sepsis in a young female patient with multiple sclerosis treated with anti-CD20 monoclonal antibody ocrelizumab.

Published in:

Infection, 2025, v. 53, n. 4, p. 1507, doi. 10.1007/s15010-025-02479-y

By:

Starosta, A. D.;
Ehler, J.;
Löffler, B.;
Tannapfel, A.;
Zipprich, A.;
Reuken, P. A.;
Stallmach, A.

Publication type:

Article

A randomized, double blind, placebo-controlled pilot study to assess the efficacy of erenumab in individuals with temporomandibular disorder.

Published in:

Journal of Oral & Facial Pain & Headache, 2025, v. 39, n. 2, p. 75, doi. 10.22514/jofph.2025.027

By:

Avila, Harold C.;
Kroenke, Kurt;
Eckert, George J.;
Gossweiler, Ana G.;
Galvez, Lorena del Carmen;
Zero, Domenick T.

Publication type:

Article

Dose finding in early-phase human immunodeficiency virus type 1 prevention monoclonal antibody clinical trials.

Published in:

Clinical Trials, 2025, v. 22, n. 4, p. 442, doi. 10.1177/17407745251347280

By:

Huang, Yunda;
Zhang, Bo;
Zhang, Lily;
Mayer, Bryan T;
Martin, Troy;
Hahn, William;
Hyrien, Ollivier;
Gelderblom, Huub C

Publication type:

Article

Calcitonin gene-related peptide monoclonal antibody treatment for new daily persistent headache.

Published in:

Journal of Headache & Pain, 2025, v. 26, n. 1, p. 1, doi. 10.1186/s10194-025-02111-2

By:

Cheema, Sanjay;
Rantell, Khadija Rerhou;
Pickering, Rachel;
Lagrata, Susie;
Kamourieh, Salwa;
Matharu, Manjit

Publication type:

Article

Population-Based Analysis of the Risk of Mycobacterial Infections Associated With Immune Checkpoint Inhibitors Open Access.

Published in:

Clinical Infectious Diseases, 2025, v. 81, n. 1, p. 176, doi. 10.1093/cid/ciae626

By:

Yan, Marie;
Hernandez, Alejandro;
Chan, Kelvin K;
Stanbrook, Matthew B;
Blanchette, Phillip S;
Johnston, James C;
Lee, Samantha M;
Macdonald, Liane;
Richard-Greenblatt, Melissa;
Marras, Theodore K;
Brode, Sarah K

Publication type:

Article

A Randomized, Placebo-Controlled Phase 2 Trial of CNTO 6785 in Chronic Obstructive Pulmonary Disease.

Published in:

COPD: Journal of Chronic Obstructive Pulmonary Disease, 2017, v. 14, n. 5, p. 476, doi. 10.1080/15412555.2017.1335697

By:

Eich, Andreas;
Urban, Veronika;
Jutel, Marek;
Vlcek, Jiri;
Shim, Jae Jeong;
Trofimov, Vasiliy I.;
Liam, Chong-Kin;
Kuo, Ping-Hung;
Hou, Yanyan;
Xiao, Jun;
Branigan, Patrick;
O'Brien, Christopher D.

Publication type:

Article

Effective treatments for respiratory syncytial virus infection in children remain elusive but prevention tools are now available.

Published in:

Drugs & Therapy Perspectives, 2025, v. 41, n. 5, p. 177, doi. 10.1007/s40267-025-01157-1

By:

Shirley, Matt

Publication type:

Article

Manage chronic hand eczema with conventional treatments, but emerging therapies show promise.

Published in:

Drugs & Therapy Perspectives, 2025, v. 41, n. 4, p. 146, doi. 10.1007/s40267-025-01155-3

By:

Zhuang-Yan, Amy

Publication type:

Article

Regulatory and clinical aspects in biosimilar medicines: comparability, extrapolation, interchangeability, and safety: Biosimilar medicines: evaluating comparability, extrapolation, interchangeability, and safety: M. C. Raposo et al.

Published in:

Drugs & Therapy Perspectives, 2025, v. 41, n. 3, p. 111, doi. 10.1007/s40267-025-01145-5

By:

Raposo, Miguel C.;
Feiteira, Cláudia;
Ribeiro, Maria H. L.

Publication type:

Article

Correction: Rozanolixizumab in generalized myasthenia gravis: a profile of its use.

Published in:

2024

By:

Hoy, Sheridan M.

Publication type:

Correction Notice

Mirikizumab in moderately to severely active ulcerative colitis: a profile of its use.

Published in:

Drugs & Therapy Perspectives, 2024, v. 40, n. 11, p. 433, doi. 10.1007/s40267-024-01114-4

By:

Fung, Simon;
Blair, Hannah A.

Publication type:

Article

Lecanemab in Alzheimer's disease: a profile of its use.

Published in:

Drugs & Therapy Perspectives, 2024, v. 40, n. 10, p. 393, doi. 10.1007/s40267-024-01108-2

By:

Blair, Hannah A.

Publication type:

Article

Adis summary of research: Omalizumab in severe asthma: effect on oral corticosteroid exposure and remodelling. A randomized open-label parallel study.

Published in:

Drugs & Therapy Perspectives, 2024, v. 40, n. 8, p. 291, doi. 10.1007/s40267-024-01083-8

By:

Syed, Yahiya Y.

Publication type:

Article

Rozanolixizumab in generalized myasthenia gravis: a profile of its use.

Published in:

Drugs & Therapy Perspectives, 2024, v. 40, n. 6, p. 203, doi. 10.1007/s40267-024-01077-6

By:

Hoy, Sheridan M.

Publication type:

Article

Aim to alleviate alopecia areata with newly available agents.

Published in:

Drugs & Therapy Perspectives, 2024, v. 40, n. 5, p. 181, doi. 10.1007/s40267-024-01069-6

By:

Fenton, Caroline;
Kang, Connie

Publication type:

Article

Mirvetuximab soravtansine in folate receptor alpha-positive, platinum-resistant ovarian cancers: a profile of its use.

Published in:

Drugs & Therapy Perspectives, 2024, v. 40, n. 2, p. 53, doi. 10.1007/s40267-024-01050-3

By:

Fung, Simon;
Syed, Yahiya Y.

Publication type:

Article

Correction to: Tezepelumab in severe asthma: a profile of its use.

Published in:

2024

By:

Syed, Yahiya Y.

Publication type:

Correction Notice

Nirsevimab in the prevention of respiratory syncytial virus lower respiratory tract disease: a profile of its use.

Published in:

Drugs & Therapy Perspectives, 2023, v. 39, n. 12, p. 413, doi. 10.1007/s40267-023-01039-4

By:

Shirley, Matt

Publication type:

Article

The PHASTER Study: Economic and Organizational Impact of Subcutaneous (SC) Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Treatment of HER2+ Breast Cancer Patients.

Published in:

Drugs & Therapy Perspectives, 2023, v. 39, n. 12, p. 432, doi. 10.1007/s40267-023-01038-5

By:

Munzone, Elisabetta;
Fabi, Alessandra;
Buono, Giuseppe;
Caputo, Roberta;
Montagna, Emilia;
Negri, Mara;
Nuzzo, Francesco;
Palazzo, Antonella;
Paris, Ida;
Conti, Luca;
Baggi, Anna;
Franzini, Jean Marie;
De Laurentiis, Michelino

Publication type:

Article

Spesolimab in generalised pustular psoriasis flares: a profile of its use.

Published in:

Drugs & Therapy Perspectives, 2023, v. 39, n. 12, p. 404, doi. 10.1007/s40267-023-01034-9

By:

Nie, Tina

Publication type:

Article

Tezepelumab in severe asthma: a profile of its use.

Published in:

Drugs & Therapy Perspectives, 2023, v. 39, n. 12, p. 393, doi. 10.1007/s40267-023-01033-w

By:

Syed, Yahiya Y.

Publication type:

Article

Ublituximab in relapsing forms of multiple sclerosis: a profile of its use.

Published in:

Drugs & Therapy Perspectives, 2023, v. 39, n. 11, p. 365, doi. 10.1007/s40267-023-01030-z

By:

Blair, Hannah A.

Publication type:

Article